Fixed-duration venetoclax plus obinutuzumab improves quality of life and geriatric impairments in FCR-unfit patients with CLL. - van der Straten L; Stege CAM; Kersting S; Nasserinejad K; Dubois J; Dobber JA; Mellink CHM; van der Kevie-Kersemaekers AF; Evers LM; de Boer F; Koene HR; Schreurs J; et al. (Blood, 2023)